InterCure Hits Record Preliminary Q3 Revenue Of $29M

InterCure Ltd. INCR INCR INCR released preliminary financial results for the third quarter of 2022, revealing record revenue estimated to be CA$39 million, 63% over the revenues of the third quarter of 2021 and sequential growth of over 6%.

Preliminary Q3 2022 Financial Highlights and Milestones

• Eleventh consecutive quarter of growth representing an annualized run rate of over CA$155 million.

• Revenue growth expected to continue in Q4 2022.

• Solid demand for Canndoc's branded products and expansion of the company’s medical cannabis dispensing operations.

• Continued expansion of the company's branded products portfolio, launching more than 10 new GMP SKUs during the quarter.

• Continued expansion of the company's medical cannabis dedicated pharmacy chain to a of total 25 locations as of the end of the third quarter.

• Continued execution of the company's global expansion plan.

The company plans to file its full financial results for the third quarter on November 15^th , 2022.

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss out on any important developments in the industry.

Photo: Benzinga; Sources: courtesy of Kindel Media via Pexels

Related News

InterCure Q2 2022 Revenue Grows 119%, What About Profit?

Clever Leaves 2Q: Neutraceuticals Up, Preparing For Cannabis Flower Exports From Colombia

Israel's Marijuana Bubble Bursts: Tel Aviv Stock Exchange Eliminates TA-Cannabis Index, Ending Three-Year High